Australian company Alterity Therapeutics (ASX:ATH) has announced encouraging results from its Phase 2 trial of ATH434, a first-in-class therapy for Multiple System Atrophy. …
Alterity Therapeutics delivers promising Phase 2 data in Multiple System Atrophy
September 15, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - Series 5. Ep.30
August 28, 2026 - - Podcast -
Sandoz earns workplace recognition amid push for medicine access
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Patients Australia puts healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Weight loss medicines drive revenue growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News